The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
Open accessAbstract
Liraglutide is a once-daily, human glucagon-like peptide-1 (GLP-1) analogue. Clinical studies have demonstrated blood glucose and weight-reducing effects, improvements in pancreatic B-cell function and a low risk of hypoglycaemic events with liraglutide [1,2]. Type 2 diabetes is associated with an increased risk of cardiovascular events. Recently, studies in patients with Type 2 diabetes have shown that native GLP-1 may also have beneficial effects on the myocardium [3] and on endothelial function [4]. We present here the effect of liraglutide on biomarkers for cardiovascular risk in patients with Type 2 diabetes, as an exploratory endpoint from a broader clinical study. The design and non-cardiovascular biomarker results of this study have been described previously [1]. The trial was carried out in accordance with good clinical practice. Briefly, 165 patients with Type 2 diabetes were randomized to either placebo or 0.65 mg, 1.25 mg or 1.9 mg liraglutide for 14 weeks. Across the four treatment arms, 17–23% of the subjects were previously treated with diet and exercise and the remaining subjects with oral glucose-lowering agents. Subjects had a mean body mass index (BMI) of 28.9–31.2 kg/m2 and mean glycated haemoglobin (HbA1c) at randomization of 8.1–8.5%. The study was powered against the primary endpoint HbA1c, but was not powered at an 80% level for a difference of 20% for the cardiovascular biomarkers discussed here. At randomization and end of study, the following additional parameters were assessed: adiponectin, leptin, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), tumour necrosis factor alpha (TNF-α), plasminogen activator inhibitor 1 (PAI-1) and B-type natriuretic peptide (BNP). The data are presented in Table 1. A significant decrease in PAI-1 and BNP levels were observed following treatment with liraglutide. There was a non-significant, but dose-dependent, reduction in hs-CRP levels. There were no treatment effects on levels of adiponectin, leptin, IL-6 and TNF-α with liraglutide. Table 1 Baseline levels and change from baseline level of cardiovascular risk markers after 14 weeks of treatment This study was part of a larger clinical trial, which showed significantly improved glycaemic control and a reduction in body weight in subjects treated with liraglutide [1]. In addition, systolic blood pressure (reduction of 8 mmHg at 1.90 mg/day vs. placebo) and plasma triglycerides (reduction of 22% at 1.90 mg/day vs. placebo) were significantly reduced [1]. PAI-1 and hs-CRP are inflammatory biomarkers that are associated with an increased risk of cardiovascular disease [5]. Elevated PAI-1 levels may suppress the fibrinolytic process and thereby be associated with the development of atherosclerosis. BNP is a marker of left ventricular dysfunction and elevated levels are risk markers for cardiovascular diseases, in particular for heart failure [6]. The findings suggest that liraglutide, when used to regulate blood glucose levels in patients with Type 2 diabetes, improves certain biomarkers associated with increased cardiovascular risk. Large prospective trials are needed to confirm these results and to assess whether these effects translate into improvements in cardiovascular risk in patients with Type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Self-citationG�de, P., Hildebrandt, P., Hess, G., Parving, H.-H., & Pedersen, O. (2005) · Diabetologia · doi:10.1007/s00125-004-1607-0 · Cited by 105
Research works printed but not linked: 4
- 10.2337/dc06-2593 · DOI · Paper page
- 10.3132/dvdr.2004.005 · DOI
- 10.1152/ajpendo.00237.2004 · DOI · Paper page
- 10.1016/j.amjcard.2005.11.010 · DOI · Paper page
Cited by
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
“As with previous liraglutide studies [23], a reduction in SBP was observed vs insulin glargine, but not in comparison with placebo.”
Self-citationon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
Metadata
- Authors
- Courrèges, J. ‐., Vilsbøll, T., Zdravkovic, M., Le‐Thi, T., Krarup, T., Schmitz, O., Verhoeven, R., Bugáñová, I., & Madsbad, S.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2008-08-29
- Volume
- 25
- Issue
- 9
- Pages
- 1129-1131
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2005230361
- Cited by
- 191
- References
- 2
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.